Cancer Research Center at Massachusetts General Hospital, 55 Fruit Street, GRJ 9th floor, Boston, MA 02114, USA.
Mol Cell Biol. 2010 Jun;30(12):3111-25. doi: 10.1128/MCB.01398-09. Epub 2010 Apr 19.
Estrogen and progesterone are the defining hormones of normal female development, and both play critical roles in breast carcinogenesis. Cyclin D1 is a breast cancer oncogene whose amplification is linked to poor prognosis in estrogen and progesterone receptor-positive breast cancers. Here we report that cyclin D1 regulates progesterone receptor expression, consequently enhancing responses to estrogen and progesterone. Estrogen treatment of cyclin D1 transgenic mice increased progesterone receptor expression and induced mammary hyperplasias that were stimulated by progesterone and blocked by a progesterone antagonist. Progesterone receptor levels decreased in cyclin D1 knockout mice. Cyclin D1 regulated progesterone receptor expression through a novel estrogen- and cyclin D1-responsive enhancer in DNA encoding part of the 3' untranslated region of the progesterone receptor gene. Small inhibitory RNAs for cyclin D1 decreased progesterone receptor expression and estrogen receptor binding to the 3' enhancer region in human breast cancer cells. Since estrogen and progesterone regulate cyclin D1, our results suggest that cyclin D1's participation in a feed-forward loop could contribute to increased breast cancer risks associated with estrogen and progesterone combinations. Additionally, its regulation of the progesterone receptor identifies a novel role for cyclin D1 in ovarian hormone control of breast development and breast carcinogenesis.
雌激素和孕激素是女性正常发育的决定性激素,两者在乳腺癌的发生中都起着关键作用。细胞周期蛋白 D1 是一种乳腺癌致癌基因,其扩增与雌激素和孕激素受体阳性乳腺癌的预后不良有关。在这里,我们报告细胞周期蛋白 D1 调节孕激素受体的表达,从而增强对雌激素和孕激素的反应。雌激素处理细胞周期蛋白 D1 转基因小鼠增加了孕激素受体的表达,并诱导了孕激素刺激和孕激素拮抗剂阻断的乳腺增生。细胞周期蛋白 D1 敲除小鼠中的孕激素受体水平降低。细胞周期蛋白 D1 通过孕激素受体基因部分 3'非翻译区编码的 DNA 中一个新的雌激素和细胞周期蛋白 D1 反应增强子来调节孕激素受体的表达。针对细胞周期蛋白 D1 的小干扰 RNA 降低了人乳腺癌细胞中孕激素受体的表达和雌激素受体与 3'增强子区域的结合。由于雌激素和孕激素调节细胞周期蛋白 D1,我们的结果表明,细胞周期蛋白 D1 参与正反馈回路可能会增加与雌激素和孕激素联合使用相关的乳腺癌风险。此外,它对孕激素受体的调节确定了细胞周期蛋白 D1 在卵巢激素控制乳腺发育和乳腺癌发生中的新作用。